Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buccal midazolam for pediatric convulsive status epilepticus in hospital or emergency settings
2020-000226-26Phase 3
- Sponsor
- Takeda
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midazolam in status epilepticus (SE) and seizure disorder, sponsored by Takeda. Primary endpoint: Response rate.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)seizure disorder
Beyond the preview
Go deeper on 2020-000226-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000226-26.